CSI Market
Sign In | Register

Spyglass Pharma Inc (SGP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SGP Annual Cash Flow →
The data below summarizes Spyglass Pharma Inc's cash flow activity from Mar 31 2025 to Jun 30 2026, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-33.68
Depreciation & amortization0.66
Amortization of Other Assets0.00
Asset impairment charges0.00
Accountig change0.00
Provision For Loan Losses Expensed0.00
Inventories0.00
Purchased in-process R & D0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation7.56
Sharebased compensation0.00
Taxes on exercise of stock options0.00
Operating Lease Right Of Use Asset Amortization Expense0.06
Gain Loss On Termination Of Lease-
Gain Loss In Fair Value Of Financial Instruments Subject To Mandatory Redemption-
Increase Decrease In Operating Lease Liability0.03
Income taxes0.00
Losses/ -gains on investments net0.00
Accounts Receivable-0.24
Increase (Decrease) in Accounts Payable1.72
Increase (Decrease) in Accrued Liabilities0.00
Other Working capital changes0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.70
Other Working Capital0.90
Other assets & liabilities0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-5.99
Discontinued operations0.00
Net Cash flow from Operating Activities-28.38
Investing Activities
Capital Expenditures-2.61
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Held-to-maturity Securities11.01
Payments to Acquire Held-to-maturity Securities-11.00
Proceeds from other investments0.00
Purchases of other investments0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Purchases of Investments0.00
Purchases of non-current assets0.00
Acquisition net of cash acquired0.00
Investment in affiliate0.00
Sale of businesses0.00
Proceeds from sale of assets0.00
Note receivable0.00
Other0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-2.60
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock157.77
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net0.00
Other net0.00
Payments Of Temporary Equity Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents96.36
Dividends paid to minority interests0.00
Dividends paid0.00
Net Cash Flow from Financing Activities157.77
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-30.99
Total Cash Flow126.79
4 historic quarters locked

Sign in to unlock the full Spyglass Pharma Inc cash flow history.

Sign In Create Free Account

About Spyglass Pharma Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 6, 2026
  • Source: sgp-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001778922-26-000045

Figures are derived from filed reports and may be restated. Historical data is subject to revision.